Please assess the completion status of the following clinical trial:

Trial Title: Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a confirmed diagnosis of AL amyloidosis based on accepted clinical and laboratory criteria.~* Patients are greater than 21 years old.~  * Female patients are not of child bearing potential or if they are of child bearing potential, they must not be pregnant or breast-feeding.~ * Patients have a life expectancy greater than 3 months.~ * Patients have an Eastern Cooperative Oncology Group (ECOG)-specified performance status of less than or equal to 3.~* Patients to be included are those with measurable, localized amyloid deposits (larynx, subcutaneous tissue, muscle, lung, lymph nodes) or clinically evident systemic disease (liver, kidney, heart, etc).~* Only patients with prior systemic therapy with relapsed/refractory disease are eligible, unless they have declined or are not eligible for high-dose melphalan and autologous hematopoietic stem cell transplant (HSCT) or any other standard therapy that has been known to be life-prolonging or life-saving.~* Patients have adequate organ function.~* Patients with cancer are eligible provided they meet specific criteria.~* Patients must provide signed, written, informed consent and be willing and able to comply with eligibility requirements, scheduled, visits, and follow-up studies.~Exclusion Criteria:~* Non-AL amyloidosis.~* Renal failure (on dialysis).~* Females who are pregnant or breast-feeding.~* ECOG Performance Status greater than 3.~* Seriously limited cardiac, renal, or hepatic function.~* Uncontrolled infection or significant co-morbidity (e.g., uncontrolled diabetes, severe diarrhea).

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase Ia (Type: EXPERIMENTAL): Administration of Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4:~A 1-patient cohort will be infused with 0.5 mg/m2 of Ch 11-1F4 and, if tolerated, the doses in the next patients will be increased to 5, 10, 50, 100, 250, and finally, 500 mg/m2. All individuals will be evaluated prior to treatment, after infusion weekly for four weeks, as well as at 8 weeks.
- Phase Ib (Type: EXPERIMENTAL): Administration of Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4:~Subjects will receive four weekly infusions of the monoclonal anti-body at Dose Level 1 (0.5 mg/m2). If tolerated, the doses in the next patients will be increased to 5, 10, 50, 100, 250, and finally, 500 mg/m2. When the highest tolerated dose is reached without toxicity in 2 patients, an additional 4 patients will be enrolled and infused at that dose. Escalation or de-escalation will continue until we have determined the highest dose level at which less than 2 patients experience toxicity. All individuals will be evaluated prior to each course of treatment, as well as at weeks 5, 8, and 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete